Compound
← Compound
Official website →
LLYELI LILLY & Co
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- LLY
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog fam…
IndustryDrug Manufacturers - General
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
38.96×
P/B
Price divided by book value
30.67×
EV/EBITDA
Enterprise value divided by operating cash generation
26.38×
EV/Revenue
Enterprise value divided by revenue
14.34×
What the company earns
ROE
Return on shareholders’ equity
92.6%
ROA
Return on all assets
18.8%
Gross margin
What remains after product costs
83.4%
Operating margin
What remains after operating the business
49.7%
Net margin
How much of each revenue unit becomes profit
33.5%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
1.62
Total debt
Sum of borrowings
$54.91B
Cash
Cash available to cover it
$8.89B
Current ratio
Short-term assets divided by short-term liabilities
1.35
Free cash flow
Cash left after investing
$7.76B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.5
Revenue growth
Compared with the same period a year earlier
47.7%
Earnings growth
Compared with the same period a year earlier
25.3%
Dividend yield
Trailing 12-month distributions divided by price
0.6%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 28.54B | 34.12B | 45.04B | 65.18B |
| Custo dos produtos | -6.63B | -7.08B | -8.42B | -11.05B |
| Despesas com vendas e administrativas | -6.44B | -7.4B | -8.59B | -11.09B |
| Pesquisa e desenvolvimento | -7.19B |
News about LLY
Motley Fool · 17 hours ago
Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016
Yahoo Finance · 17 hours ago
The Next Chapter of Eli Lilly Could Be Bigger Than Investors Expect
Bloomberg Markets · 20 hours ago
Accenture Up on Partnership with Anthropic; Novo Nordisk Falls on Turnaround | Stock Movers
Yahoo Finance · 20 hours ago
Nvidia vs. Eli Lilly: I’d Choose This Stock for the Next Decade
Yahoo Finance · 21 hours ago
Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher
Follow LLY and get agent analysis of what is moving the stock.
Open Compound